Vynleads

As a Major Heart Failure Trial Reports on Metformin, Vynleads Focuses on Daily Follow-Through Beside Clinician-Directed Care

Editor's note, October 2026: our AI wellness assistant is now called Coach Smith. This release was updated to use the new name.

Vynleads (OTCQB: VYND) shared a behavior-change perspective on the Met-HeFT trial, presented as a Hot Line result at the European Society of Cardiology (ESC) Congress 2026 in Munich. The trial found no significant evidence that metformin improves cardiovascular outcomes versus placebo in patients with heart failure with reduced ejection fraction who also have diabetes, prediabetes, or an elevated risk of diabetes.

What the Trial Reported

Met-HeFT was presented during the Hot Line 6 session at ESC Congress 2026 and announced in an official ESC press release. The trial, part of the DANHEART study, is registered at ClinicalTrials.gov (NCT03514108). Vynleads is not a clinical organization and takes no position on metformin's efficacy, safety, or appropriate use — those are clinical questions for each person's care team, and full peer-reviewed publication details should be consulted for specifics.

Daily Follow-Through Deserves Its Own Support

“Results like these will be debated by cardiologists and endocrinologists, and that is where the clinical conclusions belong. What I notice is the part that stays the same after any result: the patient still goes home to the same evening questions about dinner, a walk, sleep, stress and the next appointment. Medication plans change as evidence arrives. The daily routine runs alongside them and needs its own structure, whatever the prescription turns out to be. That parallel track is the one we built Done With Diabetes to carry, and I think it deserves the same rigor as every other part of the plan.”

— Alex Mannine, Co-Founder and CEO, Vynleads

The company's free learning library covers this ground in plain language, including starting type 2 diabetes medication, a practical type 2 diabetes daily checklist, and a guide to how to improve metabolic health.

Translating a Care Plan Into a Tuesday

The Done With Diabetes™ program pairs a structured 8-week Success Blueprint with Coach Smith, the AI wellness assistant — educational lifestyle support with human review and safety checks, never medical advice — built on the company's AI coaching technology. The program never comments on, adjusts, or second-guesses medication; it exists to make the lifestyle half of the plan durable. Learn more about Vynleads.

Vynleads is not affiliated with the European Society of Cardiology or the Met-HeFT trial. This commentary is a non-clinical business and behavior-change perspective; it does not characterize metformin's efficacy, safety, or appropriate use, and it is not medical advice.